Emfib 250 mg Gefitinib Tablets
Brand Name: Emfib
Composition: Gefitinib 250mg
Manufactured by: Emcure Pharmaceuticals Ltd.
Packing: Pack of 30 Tablets
Country Of Origin: India
WHAT IS EMFIB TABLETS?
Emfib Gefitinib is a type of drug called a tyrosine kinase inhibitor (TKI), also known as a cancer growth inhibitor. Kinases are proteins in the body that regulate how the cells grow and divide. Gefitinib blocks (inhibits) the protein from sending signals to the cancer cells that make them grow and divide.
USES OF EMFIB TABLETS:
Emfib 250mg Tablet is used to treat some people with non-small cell lung cancer (NSCLC). It only works for cancers that have an abnormal form of a protein called epidermal growth factor receptor (EGFR). Tests are done on the cancer cells from a lung biopsy or previous surgery to check the level of EGFR.
Emfib 250 mg Tablet is an anticancer medicine which is used in the treatment of cancer of the lungs. It should only be used under the supervision of a qualified physician.
POSSIBLE SIDE EFFECTS:
The following is a list of possible side effects that may occur from the use of Gefitrust Tablet. This is not a comprehensive list. These side-effects are possible but do not always occur. Some of the side-effects may be rare but serious. Consult your physician if you observe any of the following side-effects, especially if they do not go away.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the eyelids, mouth, face, lips, or tongue); cough; dark urine; dizziness; eye irritation or pain; extreme fatigue; fever; persistent diarrhea; stomach pain; swelling of the ankles or feet; yellowing of the skin or eyes.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Emfib 250mg Tablet may be taken with or without food, but it is better to take it at a fixed time.
Emfib 250 mg Tablet is an anti-cancer medication. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.
The concomitant administration of Emfib with simvastatin is contraindicated. The risk of myopathy and rhabdomyolysis is increased with combined Emfib and HMG-COA reductase inhibitor therapy. Myopathy or rhabdomyolysis with or without acute renal failure have been reported as early as three weeks after initiation of combined therapy or after several months. There is no assurance that periodic monitoring of creatine kinase will prevent the occurrence of severe myopathy and kidney damage.
Emfib AUC was reduced by 30% when Emfib 600 mg was given simultaneously with resin-granule drugs such as colestipol (5 g). Administration of the drugs two hours or more apart is recommended because Emfib exposure was not significantly affected when it was administered 2 hours apart from colestipol.